Drugs / Merotocin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02545127 | May 2021 → Nov 2022 | — | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Merotocin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02545127 ↗ |
| Action | Activate | “Merotocin (a selective oxytocin-receptor agonist)” NCT02545127 ↗ |
| Route | Intranasal | “Merotocin nasal spray 400 μg/dose” NCT02545127 ↗ |